







11. Ortiz de Frutos FJ, Torrelo A, de Lucas R, et al. Patient perspectives on triggers, adherence to medical recommendations, and disease control in atopic dermatitis: the DATOP study. *Actas Dermosifiliogr*. 2014;105:487-496.
12. Ricci G, Patrizi A, Bellini F, et al. Use of textiles in atopic dermatitis: care of atopic dermatitis. *Curr Probl Dermatol*. 2006;33:127-143.
13. Welliver RC, Wong DT, Sun M, et al. The development of respiratory syncytial virus-specific IgE and the release of histamine in nasopharyngeal secretions after infection. *N Engl J Med*. 1981;305:841-846.
14. Aquino M, Fonacier L. The role of contact dermatitis in patients with atopic dermatitis. *J Allergy Clin Immunol Pract*. 2014;2:382-387.
15. Brod BA, Treat JR, Rothe MJ, et al. Allergic contact dermatitis: kids are not just little people. *Clin Dermatol*. 2015;33:605-612.
16. Martorell A, Alonso E, Boné J, et al. Position document: IgE-mediated allergy to egg protein. *Allergol Immunopathol (Madr)*. 2013;41:320-336.
17. Sicherer SH. Early introduction of peanut to infants at high allergic risk can reduce peanut allergy at age 5 years [published online September 17, 2015]. *Evid Based Med*. 2015;20:204.
18. Kiken DA, Silverberg NB. Atopic dermatitis in children, part 1: epidemiology, clinical features, and complications. *Cutis*. 2006;78:241-247.
19. Silverberg JI, Hanifin J, Simpson EL. Climatic factors are associated with childhood eczema prevalence in the United States. *J Invest Dermatol*. 2013;133:1752-1759.
20. Sargen MR, Hoffstad O, Margolis DJ. Warm, humid, and high sun exposure climates are associated with poorly controlled eczema: PEER (Pediatric Eczema Elective Registry) cohort, 2004-2012. *J Invest Dermatol*. 2014;134:51-57.
21. Weiland SK, Hüsing A, Strachan DP, et al. Climate and the prevalence of symptoms of asthma, allergic rhinitis, and atopic eczema in children. *Occup Environ Med*. 2004;61:609-615.
22. Langan SM, Irvine AD. Childhood eczema and the importance of the physical environment. *J Invest Dermatol*. 2013;133:1706-1709.
23. Biagini Myers JM, Wang N, LeMasters GK, et al. Genetic and environmental risk factors for childhood eczema development and allergic sensitization in the CCAAPS cohort. *J Invest Dermatol*. 2010;130:430-437.
24. Brown SJ, McLean WH. Eczema genetics: current state of knowledge and future goals. *J Invest Dermatol*. 2009;129:543-552.
25. Hanifin JM. Evolving concepts of pathogenesis in atopic dermatitis and other eczemas. *J Invest Dermatol*. 2009;129:320-322.
26. Paller AS. Latest approaches to treating atopic dermatitis. *Chem Immunol Allergy*. 2012;96:132-140.
27. Silverberg JI, Norowitz KB, Kleiman E, et al. Association between varicella zoster virus infection and atopic dermatitis in early and late childhood: a case-control study. *J Allergy Clin Immunol*. 2010;126:300-305.
28. Futamura M, Leshem YA, Thomas KS, et al. A systematic review of Investigator Global Assessment (IGA) in atopic dermatitis (AD) trials: many options, no standards. *J Am Acad Dermatol*. 2016;74:288-294.
29. Schmitt J, Apfelbacher C, Spuls PI, et al. The Harmonizing Outcome Measures for Eczema (HOME) roadmap: a methodological framework to develop core sets of outcome measurements in dermatology. *J Invest Dermatol*. 2015;135:24-30.
30. Hanifin JM, Thurston M, Omoto M, et al. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. *Exp Dermatol*. 2001;10:11-18.
31. Leshem YA, Hajar T, Hanifin JM, et al. What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: an inter-rater reliability study. *Br J Dermatol*. 2015;172:1353-1355.
32. Barbier N, Paul C, Luger T, et al. Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme. *Br J Dermatol*. 2004;150:96-102.
33. Herth-Jones J. Six area, six sign atopic dermatitis (SASSAD) severity score: a simple system for monitoring disease activity in atopic dermatitis. *Br J Dermatol*. 1996;135(suppl 48):25-30.
34. Zhao CY, Tran AQ, Lazo-Dizon JP, et al. A pilot comparison study of four clinician-rated atopic dermatitis severity scales. *Br J Dermatol*. 2015;173:488-497.
35. Kunz B, Oranje AP, Labrèze L, et al. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. *Dermatology*. 1997;195:10-19.
36. Williams H, Stewart A, von Mutius E, et al. Is eczema really on the increase worldwide? *J Allergy Clin Immunol*. 2008;121:947-954.
37. Silverberg JI, Hanifin JM. Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study. *J Allergy Clin Immunol*. 2013;132:1132-1138.
38. Halvorsen JA, Lien L, Dalgard F, et al. Suicidal ideation, mental health problems, and social function in adolescents with eczema: a population-based study. *J Invest Dermatol*. 2014;134:1847-1854.
39. Mortz CG, Andersen KE, Dellgren C, et al. Atopic dermatitis from adolescence to adulthood in the TOACS cohort: prevalence, persistence, and comorbidities. *Allergy*. 2015;70:836-845.
40. Rystedt I. Atopic background in patients with occupational hand eczema. *Contact Dermatitis*. 1985;12:247-254.
41. Mortz CG, Andersen KE, Dellgren C, et al. Atopic dermatitis from adolescence to adulthood in the TOACS cohort: prevalence, persistence and comorbidities. *Allergy*. 2015;70:836-845.